文摘
摘要目的:进行荟萃分析的数据,全面调查临床和功能结果发表在中风后癫痫(PSE)患者。
背景:关键是强调对病人结果PSE的负担。而PSE据报道在中风患者恶化的结果,公布的数据是不确定的。
设计/方法:我们使用Covidence进行文献检索的研究直到1 - 3月- 2022年出版。我们使用乔安娜·布里格斯研究所队列研究的工具来评估偏差的风险。我们的结果的措施包括死亡率和糟糕的结果(兰金量表得分3 - 6)。我们报告比值比(或)和95%置信区间(CI)使用随机效应分析。发表偏倚评估使用症的测试。我们在4.2.0 R版本进行了统计分析。(普洛斯彼罗ID: CRD42022308648)
结果:我们筛选3721研究,其中包括71篇文章(N = 29759 PSE患者;17日,42083名患者没有PSE)。文章报告了3938和13067年初晚期癫痫发作;12754年发作不归类为早/晚。偏见的风险是高在两个研究中,温和的36低33。PSE死亡率的可能性大(或2.09;可信区间1.78 - -2.45;N = 52研究)和糟糕的结果(或2.39;可信区间1.91 - -3.00;N = 19研究)。 In subgroup analyses, post-ischemic stroke epilepsy was associated with mortality (OR 2.31; CI 1.88–2.83) and poor outcome (OR 2.60; CI 1.91–3.52). Post-hemorrhagic stroke epilepsy showed consistently significant OR for the poor outcome (OR 2.04; CI 1.33–3.13) but failed to reach statistical significance for mortality (OR 1.29; CI 0.96–1.74). No significant publication bias was observed for mortality (p=0.93) and poor outcome (p=0.17).
结论:我们的分析表明,PSE是死亡和严重残疾的风险增加了一倍。预防PSE应该研究优先级很高。中风严重性或损伤体积的作用还需要进一步研究。
披露:Misra先生没有披露。胡安·巴斯克斯博士没有披露。Eldem女士没有披露。卢卡斯席尔瓦没有披露。Mohadat博士没有披露。西克曼博士没有披露。汗女士没有披露。Funaro太太没有披露。克拉丽莎Yasuda没有披露。Liebeskind博士接到Cerenovus研究支持。 Dr. Liebeskind has received research support from Genentech . Dr. Liebeskind has received research support from Medtronic. Dr. Liebeskind has received research support from Stryker. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Diamedica. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Javelin. Dr. Kasner has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Kasner has received research support from Bristol-Myers Squibb. The institution of Dr. Kasner has received research support from Medtronic. The institution of Dr. Kasner has received research support from WL Gore. Dr. Mishra has nothing to disclose.
